Annexon Investor Day: ANX007 Targets C1q in Dry AMD GA as Phase III Readout Nears Q4

Annexon (NASDAQ:ANNX) used its Investor Day presentation to outline the scientific rationale and clinical progress for ...
Nasdaq

Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic ...

Potential for Vonaprument to Be the First Treatment Approved in Europe and the U.S. for Dry AMD with Geographic Atrophy Based on Protection of Visual Acuity and Structural Measures BRISBANE, Calif., ...
Nasdaq

Annexon, Inc. Completes Enrollment of Phase 3 ARCHER II Trial for Vonaprument, Targeting Vision Preservation in Dry AMD with Geographic Atrophy

Annexon, Inc. reports complete enrollment in the ARCHER II trial for vonaprument, targeting dry AMD with topline data due 2026. Annexon, Inc. announced the successful completion of enrollment for its ...